Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Hypertension, Hypercholesterolemia, Dementia Risk Factors
Interventions: Angiotensin Receptor Blockers (ARBs), Hydrophilic Statins or Non-Statin Alternative; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 50 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Spinal Cord Injuries
Interventions: Seated control (CON), Arm cycle exercise (ACE), Liquid meal; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: AEGR-733; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Los Angeles, California • Philadelphia, Pennsylvania

Conditions: Cerebrovascular Disease, Mild Cognitive Impairment
Interventions: Heart Health Intervention; Behavioral
Lead sponsor: Gregory Jicha, 323-5550; Other
Eligibility: 55 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hypercholesterolaemia
Interventions: alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio

Conditions: Hyperlipidemia
Interventions: Policosanol supplement (oral capsule) vs. placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Diabetes, Lipodystrophy, Hyperlipidemia
Interventions: Metreleptin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months to 98 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metabolic Syndrome X, Atherosclerosis, Insulin Resistance, Hyperinsulinism, Glucose Metabolism Disorders, Metabolic Disease, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions: Prolonged sitting without exercise, Prolonged sitting with interval exercise; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 40 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hyperlipidemia
Interventions: Algorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider; Other
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions: Special Intervention; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 40 Years and older
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Cholesterol, Elevated, Clinical Decision Support, Education
Interventions: Interruptive Reminder, Non-interruptive Reminder, No Reminder; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dyslipidemia, Healthy Volunteers
Interventions: TAP311; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Hypertriglyceridemia, Severe Hypertriglyceridemia
Interventions: ION775; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Lincoln, California • Aurora, Colorado • Boca Raton, Florida + 13 more

Conditions: Diabetes Mellitus, Type 2, Hyperlipidemia, Hypertension
Interventions: Physician counseling for health behavior change; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 99 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 6
States / cities: Corpus Christi, Texas • Harlingen, Texas • Laredo, Texas + 2 more

Conditions: Hypertriglyceridemia, Cardiovascular Diseases
Interventions: ISIS 678354, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more

Conditions: HIV Infections, Hyperlipidemia
Interventions: Pravastatin, Darunavir, Ritonavir, Washout; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cardiovascular Disease, Hypertension, Diabetes, Hyperlipidemia
Interventions: Pharmacist CVD; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypercholesterolemia
Interventions: alirocumab SAR236553 (REGN727); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Dyslipidemia
Interventions: AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Lipodystrophy
Interventions: Metreleptin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes, Hypertension, Hyperlipidemia
Interventions: home health/primary care collaboration; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 30 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hyperlipidemia
Interventions: Not listed
Lead sponsor: Scripps Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Severe Hypertriglyceridemia
Interventions: Pegozafermin, Placebo; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 73
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 65 more

Conditions: Cardiovascular Diseases, Myocardial Infarction, Atrial Fibrillation, Diabetes Mellitus, Heart Failure, Hyperlipidemias, Hypertension, Ischemic Heart Disease, Stroke, Transient Ischemic Attack
Interventions: Care coordination delivered based on perceived need, Care coordination delivered based on usual care (e.g. discharge from hospital); Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Vascular Intervention Strategies Trial for Alzheimer's

Postprandial Lipid Tracer and Exercise in Spinal Cord Injury

A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Policosanol for the Treatment of Hypercholesterolemia

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

The Effects of Interrupting Prolonged Sitting With Intermittent Exercise on Postprandial Lipemia

Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease

Latinos Understanding the Need for Adherence

Statin Reminders for Improving Prescribing in Primary Care

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

A Study to Assess the Safety, Tolerability and Efficacy of ION775

A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

Cardiovascular Intervention Improvement Telemedicine Study

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

Leptin to Treat Lipodystrophy

Controlling Hypertension in Diabetes- Feasibility Study

Comparison of LDL Particle Count With Other Available Lipid Tests

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination